Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

NYU Langone Health

Status: Invitation-only

Conditions: Cirrhosis; Hepatocellular Carcinoma

Treatments: Other: Auto-pended bot liver ultrasound order

Study type: Observational

Funder types: Other

Identifiers

NCT06624189

QI-Active Choice CDS

Details and patient eligibility

About

The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Enrollment: 600 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• cirrhosis diagnosis,
• 6 months or more after since most recent imaging.

Exclusion criteria

• previous liver transplant,
• HCC diagnosis,
• receiving hospice care,
• completed external imaging in the past 6 months.

Trial design

600 participants in 2 patient groups

Intervention: Auto-pended bot liver ultrasound order

Description:

Participants in the intervention group will receive an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening.

Treatment:

Other: Auto-pended bot liver ultrasound order

Control: Usual Care

Description:

Participants in the control group will not receive the auto-pended bot liver ultrasound order.